NIH Reporter #5R01AI179666-03

NIH/NIAID Solicitation for Research on Broadly Neutralizing Antibodies in HIV Treatment

This opportunity is a research solicitation from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, focused on HIV treatment: - Government Buyer: - National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) - Scope of Work: - Research on the effects of broadly neutralizing antibodies (bNAbs) at the initiation of antiretroviral therapy (ART) for HIV - Utilizes a nonhuman primate model - Requires complex sequencing and tracking of virus clonotypes - Focus on immune response and reservoir dynamics - Products/Services Requested: - Research services in immunology and infectious disease - No specific products, part numbers, or quantities specified - Unique/Notable Requirements: - Advanced immunology and virology research capabilities - Expertise in nonhuman primate models and high-throughput sequencing - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Estimated contract value: $840,170

Description

This project focuses on evaluating the effects of broadly neutralizing antibodies in HIV treatment using a nonhuman primate model. It involves complex sequencing and tracking of virus clonotypes, with a focus on immune response and reservoir dynamics. The project is funded by NIH/NIAID and is scheduled to start in August 2025, ending in July 2027. The solicitation is open for applications and aims to advance understanding in immunology and infectious disease research.

View original listing